Endocrine control of energy metabolism in the cow: the effect on milk yield and levels of some blood constituents of injecting growth hormone and growth hormone fragments

4.1 The Nitrogen Needs of Ruminants

The organizers of this symposium invited me to review factors which influence the N needs of ruminants. Such a request seems to imply that, for each class of ruminant, e.g. cattle or sheep, growing or lactating, there is a definitive N or amino acid requirement. If this is known, then diets may be formulated to provide that amount of N or amino acid and the expected level of production should be achieved. As a corollary of this approach, the determination of the nutritional characteristics of the diet, its metabolizable energy (ME), rumen degradable protein (RDP) or undegraded protein (UDP), appears to be a separate issue. While such a simplistic view has advantages for ease of diet formulation, it is unlikely to be entirely correct. In general, animal responses to increasing nutrient supply are curvilinear and do not show sharp break points defining a minimum amount of nutrient to give maximum production. Secondly, animal responses are not independent of diet and, conversely, the energy and protein values of the diet depend on the physiological state of the animal, e.g. the level of food intake influences rate of passage of digesta, the extent and site of digestion and the form of metabolites absorbed.

Partitioning of dietary nitrogen in response to feeding cereal grain supplements to dairy cows during four periods of an extended lactation

Holstein–Friesian dairy cows managed in pasture-based systems are capable of lactating for considerably longer than the traditional 300 days. However, the partitioning of dietary nutrients in the second 300 days of an extended lactation has been shown to be different from that in the first 300 days. The partitioning of dietary nitrogen (N) was investigated using two groups of eight Holstein cows in four experimental periods of 6 days, at 110, 270, 450 and 560 days in milk (DIM). During each period, cows were housed in individual stalls where N intake and output were measured. Cows in a control group received a forage-based diet ad libitum, whereas cows in a second group received 5 kg DM of cereal grain and the basal forage diet ad libitum. N intake was positively related to outputs of milk N, urinary N and faecal N, and negatively to N-use efficiency (NUE). DIM was positively related to output of urinary N and negatively related to NUE and outputs of milk N and faecal N. The partitioning of N in the second year of an extended lactation was different from that in the first year, meaning that the partitioning of N reported for cows up to 300 DIM cannot be used to accurately predict the partitioning of N in cows beyond 300 DIM. Adding grain to the diet increased total nitrogen intake but decreased NUE. However, it is plausible for the addition of cereal grain to the diet of dairy cows to increase NUE, but only when the concentration of dietary crude protein decreases and any increase in dry-matter intake is small, such that total nitrogen intake is decreased.

Reproductive and lactational responses and serum growth hormone and insulin in fine-wool ewes treated with ovine growth hormone

Eighteen mature (3 to 6 years) Debouillet × Rambouillet ewes (mean weight 79·2 (s.e. 21) kg) producing and nursing single offspring were randomly allotted to one of three groups to examine the influence of ovine growth hormone (oGH) on reproductive, hormonal and lactational responses of springlambing ewes. Each ewe received a daily subcutaneous injection of either 0, 5 or 10 mg oGH from day 11 through to day 20 post partum (day 0 = parturition). Treatment groups were subdivided into two pens (three ewes per pen) and food intake was monitored from day 1 through to day 20 post partum. On days 11 and 20 post partum, jugular blood samples were collected before and hourly for 8 h after treatment. Blood samples were also collected daily from day 10 through to day 21 post partum and on alternate days through to day 40 post partum. Milk production (oxytocin-induced hand milking) and fat and protein concentrations were determined 21 days post partum. Food intake did not differ before or during the treatment period (P > 0·05). Likewise, ewe and lamb weights were similar among treatment groups through to day 60 post partum (P > 0·05). Serum insulin did not differ before or after treatment on day 11 (P > 0·05); however, on day 20 before treatment, serum insulin was significantly higher in ewes receiving 5 (2·3 (s.e. 0·3) μg/I) and 10 (2·4 (s.e. 0·3) μg/1) mg oGH than in controls (1·2 (s.e. 0·3) μg/1) (P < 0·05). After treatment, no differences were detected in serum insulin among treatments on day 20 post partum (P > 0·05). Serum growth hormone (GH) was similar among groups before treatment on day 11 post partum; but by 8 h after treatment, serum GH was significantly elevated in ewes receiving 10 mg oGH (32·4 (s.e. 1·9) μg/1) compared with ewes receiving 5 (13·9 (s.e. 1·9) μg/1) or 0 (4·5 (s.e. 1·9) μg/1) mg oGH (P < 0·01). By 20 days after lambing, serum GH differed significantly among groups both before and after administration of exogenous oGH (P < 0·01). Ewes receiving 5 or 10 mg oGH produced 2·3 (s.e. 0·2) kg milk per day compared with 1·9 (s.e. 0·2) kg/day for controls (P < 0·10). Milk fat and protein concentrations did not differ significantly among treatments (P > 0·05), but total fat yield was higher in ewes receiving either dose of oGH (206 (s.e. 20) g/day) compared with control ewes (141 (s.e. 20) g/day) (P < 005). Serum progesterone remained less than 0·5 μg/1 in ewes through to day 40 post partum. A linear decrease was observed in interval from parturition to first observed oestrus as dosage of oGH increased (116, 108 and 102 (s.e. 6) days for ewes receiving 0, 5 and 10 mg oGH, respectively; P = 0·10). Administration of exogenous oGH to lactating. anoestrous ewes between days 11 and 20 post partum enhances milk production and may influence the interval to oestrus.

Effects of exogenous bovine somatotropin on milk yield and pasture intake in dairy cows of low or high genetic merit

The effect of recombinantly derived bovine somatotropin (bST) treatment on milk production and pasture intake was examined in 16 New Zealand Friesian cows from low or high genetic merit (breeding index) selection lines. Recombinantly derived bST was administered by 2-weekly injection of a controlled release formulation for a period of 4 weeks (weeks 16 to 19 of lactation) at a dose rate equivalent to 50 mg/day. During this period the animals were housed for 18 days with food intake being measured over the last 8 days. Treatment with bST resulted in significantly higher yields of milk, fat and protein compared with the controls. Cows from the low breeding index (LBI) line were more responsive to exogenous bST than cows of the high breeding index (HBI) line in both milk and fat yield. Milk composition was not affected by bST treatment. There was a significant increase of proportionately 0·108 in intake of freshly cut pasture between bST-treated and untreated animals during days 16 to 23 of treatment. Thus, no significant difference in calculated energy balance was observed between the bSTtreated and untreated cows. This study indicates that the genetic background of cows may be an important determinant of their response to bST treatment and that such treatment rapidly alters voluntary intake in pasture-fed cows.

The effect of injecting or infusing low doses of bovine growth hormone on milk yield, milk composition and the quantity of hormone in the milk serum of cows

The effects of administering bovine growth hormone (bGH) on milk production in cattle were examined in two experiments.

In experiment 1, a Latin-square design, three groups of four Friesian cows were injected daily with one of two doses of bGH (6 ng/kg and 30 ug/kg; 0·82 unit/mg) or with saline (control) throughout three successive 21-day periods in mid-lactation. At 30 ug/kg daily bGH stimulated a significant increase in milk yield (P < 0·001) and this response increased with the duration of treatment. Changes in the yields of milk fat, protein and lactose closely followed the changes in milk production. The concentrations of milk fat (P < 0·05) and protein (P < 0·05) rose and fell respectively during the 1st week of injections.' A daily dose of 6 ug/kg bGH failed to stimulate an increase in milk yield but milk lactose content was reduced (P < 0·05) during the 2nd and 3rd weeks of treatment. The proportion of milk serum samples containing detectable quantities of the hormone was increased by the higher dose of bGH.

In experiment 2 the milk yields of four Friesian cows were measured when bGH (21·0 to 37·9 mg/day) or saline was infused intravenously for 6 days. The infusions produced up to eight-fold increases in plasma bGH. These were within physiological limits, and remained at elevated levels throughout the 24-h period. Three of the cows demonstrated a clear increase in milk production.

Use of plasma hormone and metabolite levels to predict breeding value of young bulls for butterfat production

The purpose of the experiment was to investigate the possibility of using concentrations of hormones and metabolites in plasma of potential breeding bulls early in life as indirect selection criteria for butterfat production. Sixteen Red Danish bull calves were included in the experiment, 10 were offspring of parents selected for high butterfat production for two or three generations, and six were from parents selected for low butterfat yield. The average estimated relative breeding values of the calves in the two groups were 111 and 91.

At 3·5 and 7 months of age blood samples were collected every 6 h during 2 days of ad libitum feeding, 5 days of fasting and 2 days of refeeding. The samples were analysed for glucose, urea, free fatty acids, insulin and thyroxine. At 3·5 months plasma concentrations of free fatty acids were significantly correlated with breeding value under all feeding conditions examined. The increase in plasma glucose during refeeding at both ages was positively related to breeding value. Plasma insulin during the 1st day of fasting was positively correlated with genetic merit at 3·5 months of age and negatively correlated at 7 months. Plasma thyroxine was negatively correlated with breeding value at both ages, but the correlation was only significant at 7 months. Multiple regression analyses showed that a large part of the variation in breeding value for butterfat production could be described by plasma levels of hormones and metabolites when more than one variable was included in the model. With six variables in the model 0·67 and 0·73 of the variation could be accounted for at 3·5 and 7 months of age respectively.

The results of the experiment have to be considered with caution because only one sire was used per group, the parents were preselected, and the number of animals was small. The results, however, do indicate that plasma levels of hormones and metabolites in the early life of potential breeding bulls, measured after suitable physiological challenges, may be useful as selection criteria for butterfat production of their offspring.

The effects of exogenous bovine growth hormone and bromocriptine on growth, body development, fleece weight and plasma concentrations of growth hormone, insulin and prolactin in female lambs

In crossbred female lambs given a concentrate diet ad libitum between 8 and 20 weeks of age, daily subcutaneous injections of 0·1 mg bovine pituitary growth hormone (GH) per kg live weight increased daily live-weight gain (347 v. 284 g/day; P < 0·01; no. = 8), food conversion efficiency (3·94 v. 4·49 kg dry matter per kg gain; P < 0·01) and greasy fleece weight (1·49 v. 0·99 kg; P < 0·001). The increase (4·8 kg) in final live weight was due primarily to an increase in the non-carcass components of the body (3·5 kg), with little effect on carcass weight (1·3 kg). However, bovine GH treatment markedly increased the weights of lean tissue (11·4 v. 9·2 kg; P < 0·001) and bone (2·8 v. 2·4 kg; P < 0·001) and moderately reduced the weight of fat (7·0 v. 8·0 kg; P < 0·10) in the carcass. The bovine GH treatment raised plasma concentrations of immunoreactive GH within the physiological range for about 16 h each day and significantly increased mean plasma concentrations of insulin and prolactin. Daily injection of 1 mg bromocriptine had no effect on daily live-weight gain, food conversion efficiency or carcass composition. This treatment markedly reduced plasma concentrations of prolactin but also significantly reduced insulin concentrations. When given in combination with bovine GH, bromocriptine reduced the GH-induced stimulation of insulin concentration and tended to decrease the effects of GH on food conversion efficiency and growth. This interaction was significant only for the effects on greasy fleece and skin weights (P < 0·01).

Somatomedin C in dairy cows related to energy and protein supply and to milk production

Somatomedin C and other hormones, as well as blood metabolites, were measured during the dry period and during lactation in dairy cows, given different amounts of energy and protein, to study metabolic and endocrine adaptations. Somatomedin C, specifically measured by radioimmunoassay after separation from its binding protein, did not exhibit typical diurnal variations, in contrast to somatotropin and insulin, which increased particularly after concentrate intake. Somatomedin C markedly decreased at parturition and reached lowest values around the peak of lactation, while levels of somatotropin, nonesterified fatty acids and ketone bodies were high and those of glucose, insulin, thyroxine and triiodothyronine were low. Thereafter somatomedin C values slowly increased up to the 12th week of lactation and remained elevated. Low energy and protein balances were characterized by particularly low somatomedin C concentrations. An additional protein deficit at peak lactation, when cows were already provided with low amounts of energy, did not further decrease somatomedin C levels. However, when high amounts of energy were given in the form of starch or crystalline fat, somatomedin C increased. Overall, there was a positive correlation of somatomedin C primarily with energy, but also with protein balances and a negative correlation with milk yield. Conversely, somatotropin increased markedly after parturition and was positively correlated with milk production and negatively with protein and energy balances. Thus, somatomedin C levels were paradoxically low in the presence of high circulating somatotropin. Insulin most closely paralleled somatomedin C levels. Therefore the anabolic state of metabolism at the end of pregnancy was characterized by high somatomedin C and insulin and relatively low somatotropin, whereas the catabolic state of early lactation was characterized by high somatotropin, low somatomedin C, insulin and thyroid hormones.

Plasma metabolite and hormone concentrations in Friesian cows of differing genetic merit measured at two feeding levels

Physiological differences between cows in hormone and metabolite concentrations were sought that may account for genetic differences in milk production.

Two groups of New Zealand Friesian cows, differing in genetic merit for fat production (high breeding index (HBI) and low breeding index (LBI)) by approximately 23 breeding index units (20 kg fat on the United Kingdom improved contemporary comparison scale), were each divided into two further groups, one of which was given freshly cut pasture to appetite and in the other intake was restricted to 70% of appetite. Eighteen blood samples were collected over a 24-h period from each of 16 cows fitted with indwelling jugular catheters. Samples were analysed for growth hormone, insulin, free fatty acids and β-hydroxybutyrate. Mean concentration of insulin was significantly higher in the HBI underfed group than in any other group (P < 0·01). Glucose concentration was significantly lower in the LBI group (P < 0·05), whose intake was restricted. The concentration of (3-hydroxybutyrate was significantly higher in the cows whose intake was restricted (P < 0·01) and the concentration fell markedly after feeding. Growth hormone concentrations were higher in the cows on restricted intake (P < 0·05) and in HBI cows but the differences were not statistically significant.

It was concluded that different patterns of blood metabolites and hormones are associated with cows that differ in genetic merit. Aspects of insulin and glucose metabolism, particularly at low planes of feeding, appear to offer most promise as indicators of high milk-solids production.

Hormonal and Lactational Responses to Growth Hormone-Releasing Hormone Treatment in Lactating Japanese Black Cows

Ten multiparous lactating Japanese Black cows (beef breed) were used to evaluate the effects of bovine growth hormone-releasing hormone (GHRH) analog on milk yield and profiles of plasma hormones and metabolites. The cows received 2 consecutive 21-d treatments (a daily s.c. injection of 3-mg GHRH analog or saline) in a 2 (group) x 2 (period) Latin square crossover design. The 5 cows in group A received GHRH analog during period 1 (from d 22 to 42 postpartum) and saline during period 2 (from d 57 to 77 postpartum), and those in group B received saline and GHRH analog during periods 1 and 2, respectively. Mean milk yield decreased in saline treated compared with that during the 1-wk period before treatment 7.4 and 19.1% during periods 1 (group B) and 2 (group A), respectively. Treatment with GHRH analog increased milk yield 17.4% (period 1, group A) and 6.3% (period 2, group B). Treatment with GHRH analog induced higher basal plasma concentrations of growth hormone (GH), insulin-like growth factor-1 (IGF-1), insulin, and glucose compared with saline-treated cows. In glucose challenge, the GHRH analog-treated beef cows had greater insulin secretion than the saline-treated beef cows. In insulin challenge, however, there were no significant differences in the areas surrounded by hypothetical lines of basal glucose concentrations and glucose response curves between GHRH analog- and saline-treated cows. These results demonstrate that GHRH analog treatment facilitates endogenous GH secretion in lactating Japanese Black cows, leading to increases in milk yield and plasma concentrations of IGF-1, insulin, and glucose.

Breed differences in growth hormone and insulin secretion between lactating Japanese Black cows (beef type) and Holstein cows (dairy type)

This study was performed to clarify the levels of growth hormone (GH) and insulin (INS) secretions and the glucose response to INS during lactation in a representative beef breed in Japan, Japanese Black cows, and to compare them with their counterparts in a dairy breed, Holstein cows. Six Japanese Black and seven Holstein primiparous cows received a single intravenous injection of GH-releasing factor (GRF; 0.25 microg/kg), glucose (112.5 mg/kg), or INS (0.2 U/kg) from late pregnancy (2 weeks antepartum) to mid-lactation (6 months postpartum). Japanese Black cows had one-tenth of the total milk yield of Holstein cows during lactation, and significantly lower GRF-induced GH and higher glucose-induced INS secretions than Holstein cows at all stages. In Japanese Black cows, even with lactation, these secretions remained essentially unchanged, whilst Holstein cows showed higher GH and lower INS secretions after the onset of lactation as compared with cows in late pregnancy. Both breeds had similar glucose response to INS at the respective stages. These results suggest that, during lactation, Japanese Black cows may minimize the catabolic effects of GH and sustain the anabolic effects of INS, in contrast with Holstein cows, but have similar ability to inhibit INS-mediated glucose utilization in peripheral tissues to Holstein cows.

The effects of genetic and phenotypic production potential on response to recombinant bovine somatotropin

Evidence was sought for an interaction between both phenotypic and genetic production potential and response of milk production to administration of bST in three trials of 38, 43, and 35 cows. In each trial, bST was administered in doses of 0, 10.3, 20.6, and, in trial 1 only, 41.2 mg/d for 38 wk from wk 4 of lactation. Data were analyzed for each experiment separately and combined across experiments. Analyses included separate regressions for treated and untreated animals for milk production during the production period on pretreatment production and estimated breeding value for milk production. Breeding value was estimated as the sire's estimated transmitting ability plus one-half of the maternal grandsire's estimated transmitting ability. With the exception of regression on estimated breeding value in trial 1 and in combined data, differences between treated and untreated animals in the regression of milk production on pretreatment milk production or on estimates of breeding value were not statistically significant. However, regressions on pretreatment production were substantially lower for treated than for untreated animals in each of the three trials. Regressions on breeding value estimated from sire and maternal grandsire estimated transmitting abilities were substantially, but not significantly, lower for untreated than for treated animals in all three trials. The results suggest that cows with high production potential for nongenetic reasons may show diminished response to bST, whereas cows with genetically high production potential show enhanced response. However, borderline statistical significance argues for considerable further examination before drawing firm conclusions.

Recombinant bovine somatotropin with lactating cows fed diets differing in energy density

Sixty-four Holstein cows (32 primiparous) were assigned randomly at parturition to one of two diets differing in forage:grain ratio and were further assigned to either control or treatment with recombinant bST. A full lactation study was conducted. Total mixed rations consisted of alfalfa silage, high moisture ear corn, soybean meal, and vitamin and mineral supplements. Percentages of forage in the diet (dry basis) for the high and medium energy diets were wk 1 to 12, 38.2 and 58.2; wk 13 to 26, 48.2 and 68.2; and wk 27 to 44, 68.2 and 88.2. Injection of a saline placebo or 20.6 mg/d per cow of bST started at wk 13 and stopped at wk 43 of lactation. Administration of bST increased 305-d milk yield by 19.9 and 18.3% for multiparous cows fed high and medium grain diets and by 13.0 and 5.9% for primiparous cows fed the same diets. Body weight gain during lactation tended to be lower for cows treated with bST, and body condition scores were significantly lower for those treated with bST and fed the medium energy diets. Daily injection of bST did not change concentrations of glucose or urea in blood or beta-hydroxybutyrate in plasma. Multiparous cows had a transitory increase in plasma FFA concentration immediately after bST treatment started. Milk composition, health, and reproductive parameters observed were not adversely affected by bST administration. Cows fed low energy diets during bST administration in the first lactation did not produce as much milk as controls when compared during the first 10 wk of their second lactation.

Metabolic responses to exogenous bovine somatotropin in Friesian cows of low or high genetic merit

Basal hormone/metabolite concentrations and responses to intravenous challenges of glucose, insulin and epinephrine were examined in Friesian cows from selection lines of low or high genetic merit treated with recombinantly-derived bovine somatotropin (bST) or control formulation in a 2 x 2 factorial design. Cows from the low genetic merit (low breeding index, LBI) line had previously been shown to be more responsive to the galactopoietic effects of bST (50 mg/day) than those from the high breeding index (HBI) line. Despite this, comparisons of metabolic differences were not confounded by differences in energy balance because bST treatment had also caused an increase in voluntary intake of cut pasture. Circulating levels of somatotropin, insulin-like growth factor-I (IGF-I) and insulin were greater in bST-treated than control cows but neither bST treatment nor selection line influenced basal concentrations of glucose, non-esterified fatty acids (NEFA), beta-hydroxybutyrate, urea or creatinine. Treatment with bST produced a small increase in sensitivity of cows to the lipolytic effects of epinephrine and this effect was similar in both selection lines. HBI cows had greater circulating insulin levels following the glucose challenge than LBI cows but bST treatment did not affect the insulin response to exogenous glucose. Whereas bST treatment retarded the glycogenolytic response to epinephrine and the clearance of blood glucose in response to insulin in LBI cows, it had no effect on epinephrine-stimulated glycogenolysis, and caused enhanced glucose clearance in response to insulin, in HBI cows. Results are consistent with bST altering the homeorhetic control of metabolism but do not adequately explain the greater responsiveness of LBI cows to the galactopoietic effects of bST.

Somatotropin treatment for a second consecutive lactation

Twenty-five Holstein cows were used to examine effects of recombinant bST administration for a second successive lactation on milk yield and composition, BW change, body condition, and health. Treatments were 0 (physiological saline), 10.3, 20.6, and 33 mg bST/d (8, 8, 7, and 3 cows per treatment, respectively). Saline and bST were given daily as subcutaneous injections beginning 4 to 5 wk postpartum and continuing for 38 wk. Somatotropin increased 3.5% FCM yield linearly from 8 to 36% over controls (control FCM was 30.1 kg/d). Milk composition was not affected by bST except that milk from cows given the 10.3-mg dosage had slightly higher Ca and P contents than did milk from cows receiving 0 or 20.6 mg. Cows receiving bST were 9 to 30% more efficient than controls in converting feed to milk. Body weight gain was unaffected by treatment. Average condition score was unchanged for control cows during the first 84 d following initiation of treatment, but declined in cows given bST. Thereafter, condition score increased in a similar manner for all groups. No treatment-related patterns were found in incidence of mastitis, feet and leg problems, ketosis, or milk fever. Blood hormone, chemistry, and hematology revealed no effects of bST treatment other than to raise plasma bST concentrations. Under conditions of this experiment, use of bST during a second consecutive lactation did not change the normal physiology or productive capacity of lactating cows.

Lactation response of dairy cows receiving bovine somatotropin via daily injections or in a sustained-release vehicle

Three experiments were conducted to characterize metabolic and milk production responses of dairy cows receiving recombinantly derived bovine somatotropin administered either by daily injection or in a sustained-release vehicle. In Experiment 1, somatotropin (25 mg/d) purified by two methods was given by daily injection for 14 d and resulted in 3.5 and 3.8 kg/d more milk than controls. Percentages of fat and total solids in milk were also increased by somatotropin. Eleven hematology indices and 12 metabolites, minerals, and enzyme activities in serum were unaffected by somatotropin. In Experiments 2 and 3, somatotropin was administered in a sustained-release vehicle during an 84-d treatment period. In Experiment 2, administration of 960 mg of somatotropin at 28-d intervals increased milk and SCM yields by 4.1 and 3.3 kg/d compared with yields of controls. There were no significant differences in other production parameters. In Experiment 3, 320, 640, and 960 mg somatotropin were each administered in the sustained-release vehicle at intervals of 14, 21, and 28 d. An uninjected group served as control. Cows receiving somatotropin averaged 3.5 to 5.9 kg/d more milk than controls across all injection intervals. Among doses, milk yield was greater at 960 mg than at 320 or 640 mg. There were no significant differences in milk or SCM among injection groups. These experiments demonstrate the comparable efficacy of somatotropin when given by daily injections or in a sustained-release vehicle.

Treatment of dairy cows with recombinant bovine somatotropin: genetic and phenotypic aspects

Thirty-four multiparous and primiparous Holstein cows were utilized to examine the association between the response to long-term administration of recombinant bovine somatotropin and the cow's phenotypic and genetic production potential. Cows representing a range of phenotypic and genetic production potentials were assigned to one of four treatment groups: 0, 12.5, 25.0, or 50.0 mg recombinant bovine somatotropin daily. They were injected daily for 266 d beginning on d 24 to 35 postpartum. Pretreatment milk and fat yields were used to predict daily yields over the lactation and allowed treatment groups to serve as their own controls. Actual minus predicted yield estimated the response to treatment for milk, fat, and FCM for each cow. Milk composition (fat, protein, and lactose percentage) was not significantly affected by treatment. Response in yield for milk, fat, and FCM was significant during the treatment period (266 d). Milk yield increased by 18.5, 19.9, and 21.4%; fat yield increased by 13.4, 20.3, and 18.1%; and FCM increased by 16.3%, 19.7%, and 21.1% after receipt of 12.5, 25.0 and 50.0 mg recombinant bovine somatotropin, respectively. Differences in response were not significant. The dramatic effect recombinant bovine somatotropin has on production requires that alternative approaches be adopted in the future for accurate genetic evaluation of sires and dams if somatotropin is discriminantly used in the national herd.

Insulin-like growth factor I (somatomedin C) in goats during normal lactation and in response to somatotropin treatment

1. Two experiments were performed. In Experiment 1, IGF-I concentrations in serum were followed in four lactating dairy goats during normal lactation and before, during and after 14 days of daily administration of 10 IU recombinant bovine somatotropin, starting 10 weeks post-partum. In Experiment 2, IGF-I was measured in single blood samples obtained from 40 dairy goats in the first part of lactation. 2. Measured IGF-I concentrations ranged from 4.4-9.0 nM. Concentrations varied during the day with coefficients of variation from 8.9 to 18.4% in the four goats in Experiment 1. There were no systematic trends in the diurnal variations (P greater than 0.75). 3. Concentrations of IGF-I remained fairly constant in all goats in Experiment 1 during the lactational period, and were not related to the changes in milk yield (P greater than 0.65). Similarly, no relationship was found in Experiment 2 between level of milk production and IGF-I concentration in serum. 4. Somatotropin treatment stimulated milk yields by 14 +/- 2.9% (P less than 0.05) and IGF-I concentration by 27.9 +/- 6.7% (P less than 0.05). 5. IGF-I is the most likely factor which increases mammary gland synthetic capacity in response to somatotropin treatment, and thus is responsible for the galactopoietic effect of this hormone being exerted. 6. However, serum IGF-I may primarily be involved in regulation of nutrient partitioning during normal lactation, but a paracrine synthesis with local effect on the mammary gland cannot be ruled out.

Effects of exogenous ovine growth hormone on reproduction, serum hormone profiles and milk characteristics in early-postpartum fine-wool ewes nursing single or twin offspring

After parturition (Day 0), 31 mature spring-lambing, fine-wool ewes were randomly allotted to one of six groups. Treatments were lambs suckled (one or two) and ovine growth hormone (oGH; 0, 5 or 10 mg). Growth hormone was administered subcutaneously daily from Days 6 to 25. Milk characteristics were determined on Day 26. Ewes were observed for estrus beginning on Day 27. Serum insulin did not differ (P > 0.10) between suckling intensity before or after oGH treatment on Days 6, 15 or 25. Likewise, no difference (P > 0.10) in serum insulin was detected among ewes receiving 0, 5 or 10 mg oGH. Ewes suckling twins had higher (P < 0.05) serum growth hormone on Day 6 (before beginning oGH treatment) than ewes suckling single lambs. In ewes receiving 0, 5 and 10 mg oGH, serum growth hormone differed (P < 0.01) in a linear fashion 1 h after treatment was initiated on Day 6 and continued through Hour 6. Serum growth hormone on Days 15 and 25 differed among groups both before and after oGH was administered (P < 0.01). Suckling intensity did not affect (P > 0.10) milk or milk protein and fat yields; however, oGH increased (linear, P < 0.05) fat but did not affect milk or protein yields. Interval from parturition to estrus did not differ (P > 0.20) in ewes suckling single or twin offspring. Likewise, no differences (P > 0.20) in interval length were noted in ewes receiving 0, 5 or 10 mg oGH. Suckling intensity and oGH administration for 20 d had little effect on postpartum interval or milk characteristics during the first 30 d after lambing in fine-wool ewes.

Long-term evaluation of a prolonged-release formulation of N-methionyl bovine somatotropin in lactating dairy cows

Eighty Holstein cows (first, second, or third lactation) were used to evaluate the efficacy of a prolonged-release formulation for sometribove (n-methionyl bovine somatotropin). Cows were fed ad libitum a complete mixed diet and milked twice daily. Cows were allocated randomly by parity to two treatment groups receiving 500 mg sometribove in a prolonged release formulation or excipient at 14-d intervals starting at 60 +/- 3 d postpartum and continuing for 36 wk. Treatment with sometribove increased FCM yield to a similar extent (11.4%, +3.1 kg/d) in primiparous and multiparous animals. Milk content of lactose, fat, ash, and Ca was not affected, but protein and phosphorous were slightly greater (less than 5%) in milk from sometribove-treated cows. Within a 14-d injection interval, animals treated with sometribove displayed a cyclic pattern in milk yield, but a similar pattern was not evident in feed intake.

Reproductive, hormonal and milk characteristics in ewe lambs treated with ovine growth hormone before breeding

One month before a fall breeding season, 30 6-mo-old fine-wool ewe lambs were allotted to one of three treatment groups consisting of either 0, 2.5 or 5 mg ovine growth hormone (oGH) daily for 10 d and then, on alternate days, for an additional 20 d. Five ewes from each treatment group were bled at hourly intervals for 8 h on Days 0 (first day of treatment), 9, 19 and 29. Milk yield and composition were examined on Day 21 post partum. Neither feed intake nor ewe weights differed (P > 0.20) among treatments. Serum insulin did not differ (P > 0.20) among treatments before or during the 5 h following treatment on Day 0 or 29; however, 6, 7 and 8 h after oGH administration, a linear, dose-dependent increase (P < 0.10) in serum insulin was noted. On Day 9, serum insulin differed linearly (P < 0.10) before and after treatment. On Day 19, serum insulin differed (P < 0.10) among the groups 2, 3, 6, 7 and 8 h following oGH treatment. One hour after treatment on Day 0, serum GH increased linearly (P < 0.01) among groups. Serum GH continued to rise 3 h after treatment and remained elevated through Hour 8 in ewes receiving oGH. Serum GH was increased (P < 0.01) before and after oGH administration on Days 9, 19 and 29 in GH-treated ewes. Percentage of ewes that cycled during treatment or breeding as determined by serum progesterone was similar (P > 0.20) among groups. Pregnancy rates did not differ (P > 0.20) in ewe lambs receiving 0 (70%), 2.5 (80%) and 5 (60%) mg oGH. No differences were detected (P > 0.40) in milk yield or composition among treatments. In fine-wool ewe lambs treated with 2.5 or 5 mg of exogenous oGH for 30 d before breeding, neither reproductive performance nor subsequent milk production were enhanced; however, these treatments increased serum GH and insulin.

Effects of recombinant bovine somatotropin on milk production, body composition, and physiological parameters

Twenty-eight multiparous Holstein cows were utilized to determine effects of long-term administration of recombinant bovine somatotropin on lactational performance, body condition, body composition, hormones, blood constituents, and physiological parameters. Treatments were 0 (control), 10.3, 20.6, and 41.2 mg recombinant bovine somatotropin administered daily as subcutaneous injections beginning 4 to 5 wk postpartum and continuing for 38 wk. A total mixed diet of 28% corn silage, 22% alfalfa hay cubes, and 50% corn-soybean meal-based grain mixture was fed. Fat-corrected milk yields were increased 12 to 25% for cows treated with somatotropin as compared with controls (29.9 kg/d). Milk composition was similar among treatments. Cows receiving somatotropin consumed 4 to 10% more feed and were 11 to 17% more efficient than controls for conversion of feed to milk. Body weight changes were not significantly different among treatments, but cows receiving somatotropin gained 4 to 10% less weight than controls. Body fat (kg) of cows receiving 20.6 and 41.2 mg/d was less than that of cows receiving 10.3 mg/d or no somatotropin. Estimated weights of body protein and mineral, most blood constituents, respiratory rates, and body temperature were not affected by somatotropin administration. Plasma fatty acids were elevated and hematocrit values were reduced. Plasma insulin, serum somatotropin, and heart rate increased concurrently with somatotropin administration.

Impact of somatotropin and other biochemical products on sire summaries and cow indexes

This paper outlines the potential impact of bovine somatotropin on dairy cattle improvement programs and pinpoints research needs. Recording of manufacturer, dosage, and date of start and finish of somatotropin administration is recommended in order to allow analysis of data for cow and sire ranking. Alternatives, such as restriction of somatotropin administration to certain lactations or parts of the cow's lactation are discussed. Cooperator herds or nucleus breeding schemes as alternatives to the random sampling of AI bulls may become more practical if somatotropin is widely used in the future.

Covalent coupling of bovine growth hormone to its receptor in bovine liver membranes

The structure of bovine somatotropin receptor was examined following covalent coupling of iodinated recombinant bovine growth hormone ([125I]rbGH) to bovine liver membrane receptors using ethylene glycol bis(succinimidyl succinate). Iodinated rbGH was incorporated into a complex of estimated Mr of 140,000 under reducing conditions. Excess unlabeled rbGH, but not bovine prolactin (bPRL), inhibited completely the incorporation of [125I]rbGH into the Mr = 140,000 species. In dairy bulls, the Mr = 140,000 complex was undetectable soon after birth but became predominant at 6 months of age. No evidence was found to support presence of bPRL receptors in steer liver membranes. Assuming a 1:1 stoichiometry of hormone binding to receptor, it appears that bGH binds to a major receptor subunit of Mr = 119,000 which does not recognize bPRL.

Effect of chronic growth hormone treatment on responses to epinephrine and thyrotropin-releasing hormone in lactating cows

Bovine growth hormone was administered to four Holstein cows (late lactation) in a Latin square. Treatments were 1) control, subcutaneous injection of placebo, 2) subcutaneous injection of 25 IU growth hormone on alternate days, 3) daily subcutaneous injection of 25 IU growth hormone, and 4) continuous subcutaneous infusion of 25 IU/d growth hormone. Intravenous challenges of epinephrine and thyrotropin-releasing hormone were administered separately on the 1st d after a 12-d interval of growth hormone treatment. Baseline concentrations of nonesterified fatty acids in plasma were not affected by growth hormone treatment. However, release of nonesterified fatty acids to epinephrine challenge was positively related to amount of growth hormone in plasma during treatment and was correlated with milk fat yield and milk energy secretion. Growth hormone release following thyrotropin-releasing hormone was negatively related to amount of growth hormone in plasma during treatment. Release of prolactin to thyrotropin-releasing hormone challenge was not related to average daily dose of exogenous growth hormone. The galactopoeitic action of growth hormone may be partly attributable to its effects on responsiveness of adipose tissue to a lipolytic stimulus but apparently is not associated with changes of pituitary sensitivity to thyrotropin-releasing hormone. Results are consistent with growth hormone functioning as a homeorhetic control of nutrient partitioning.

Effect of growth hormone on milk yields and related physiological functions of Holstein cows exposed to heat stress

Responses of milk production and other physiological functions to daily subcutaneous injections of bovine growth hormone (16.6 mg/cow) were studied in six Holstein cows in midlactation under environmental heat stress. Five days were assigned for each treatment of thermoneutral (18.3 degrees C), heat (28.9 degrees C), heat plus growth hormone, and heat. Each period was preceded by at least 3 days of adjustment. Feed and water were available ad libitum. Feed intake, milk production, and rectal temperature were measured twice daily. Blood, energy metabolism, and body weight were measured every 1st, 3rd, and 5th day of each period. Administration of growth hormone under heat stress increased milk production by 3.8 and 12% and fat yield by 9.5 and 12.7% over heat and heat. Feed intake declined by 5.8% with no significant increase of heat production or body weight loss during treatment with bovine growth hormone. Heat increased somatic cell concentration.

Effect of dose of bovine growth hormone on lactation of dairy cows

We administered bovine growth hormone to six Holstein cows in a Latin square design to study the relationship between dose of growth hormone and response of milk yield. Treatments were 0, 5, 10, 25, 50, and 100 IU/day of pituitary-derived bovine growth hormone administered in once-daily subcutaneous injections. Feed intake and yield of milk and milk components were measured for the last 5 days of each 10-day injection period. Yields of milk, protein, and fat increased in a dose-responsive fashion up to 32, 27, and 46% (for the 100 IU treatment) above control (26.7, .90, and .98 kg/day). Concentration of lactose in milk was not influenced by treatment, but at larger doses of growth hormone, milk fat percent was elevated and protein percent declined. As a result, milk energy secretion in response to 100 IU/day was increased 37% from control (19.2 Mcal/day). Both energy and nitrogen balance decreased with increasing growth hormone. Limited blood samples (timed to coincide with peak concentration of growth hormone postinjection) indicated treatment did not affect concentrations of glucose or insulin in blood plasma but increased concentration of growth hormone. Concentration of nonesterified fatty acids in blood plasma was increased slightly only at the 100 IU/day dose for which energy balance was negative.

Glucagon, insulin, growth hormone, and glucose concentrations in blood plasma of lactating dairy cows

Concentrations of glucose, growth hormone, insulin, and glucagon in blood plasma relative to days in milk, milk production, type of housing, and season were measured. Blood samples were obtained from 133 to 150 lactating Holstein cows on 3 consecutive days in July, October, January, and April. Glucose, insulin, and ratio of insulin to glucagon increased with increasing days in milk. Growth hormone and ratio of growth hormone to insulin decreased with increasing days in milk. Glucagon concentrations were similar throughout lactation. Above average milk production throughout lactation was associated with above average glucagon, lower insulin, and lower glucose. The relationship was not significant between growth hormone concentration and milk production, however. Cows on summer pasture with limited grain supplement had higher growth hormone and lower glucose, insulin, and glucagon than cows eating ad libitum in barns or feedlot. In general, however, all cows had higher glucose and lower growth hormone, insulin, and ratio of insulin to glucagon in July than in cooler months.

Blood and milk lipid responses induced by growth hormone administration in lactating cows

Nine multiparous Holstein cows (average 5.8 yr, 63 to 132 days postpartum) were in a 28-day single reversal experiment in the Beltsville open circuit respiration chambers with two 14-day injection periods (placebo versus bovine growth hormone, 51.5 IU/day). With growth hormone treatment, milk fat percentage increased 25 to 29%, milk fat yield increased 41%, and cows averaged -13.7 Mcal/day energy balance. There were small increases of triglycerides and 1,2-diglycerides, core lipids, and small decreases of cholesterol and phospholipids, the membrane lipids. Fat from growth hormone treatment had 6% less short (6:0, 8:0, 10:0) and medium (12:0, 14:0, 14:1, 15:0, 16:0) chain fatty acids and 6% more long chain 18:1 fatty acids. Plasma of cows treated with growth hormone had an increase of concentrations of free fatty acids, but no shifts were apparent among other lipid classes. Analysis of total plasma fatty acids did not show any net changes, but within individual plasma lipid classes, 18:1 increased and 18:2 decreased. Overall changes of blood and milk lipids are consistent with the concept that adipose tissue reserves were mobilized in response to hormone treatment and that these mobilized lipids were the major carbon source for the 41% increase of milk fat secretion. Increases of de novo synthesis of short and medium chain fatty acids also occurred but much less. Cows treated with growth hormone were in negative energy balance, and the mechanism may differ when cows are in positive energy balance.

Human growth hormone but not ovine or bovine growth hormones exhibits galactopoietic prolactin-like activity in organ culture from bovine lactating mammary gland

Explants from the mammary gland of 6 lactating cows were cultured in M-199 medium containing insulin (1.0 micrograms/ml) and hydrocortisone (0.5 micrograms/ml) and supplemented with bPRL (0.2-1.0 micrograms/ml) or oGH (0.1, 0.5 and 2.5 micrograms/ml) or bGH or hGH (0.2 and 1.0 micrograms/ml). It was found that neither oGH nor bGH significantly increased (P less than 0.05) the casein and fat synthesis and alpha-lactalbumin secretion above the control level. A significant and almost equal increase was, however, observed in the presence of bPRL and hGH, but was not influenced by the simultaneous addition of oGH to bPRL-containing medium (both at 0.5 micrograms/ml). Various hormonal treatments did not affect casein secretion and glucose uptake. High correlations (r = 0.89-0.97) were found between the mean values for casein and fat synthesis and alpha-lactalbumin secretion. Our results suggest that (a) the in vivo galactopoietic activity of bGH does not result from a direct effect of synthetic capacities on the mammary gland, and (b) hGH is a potent lactogen in the organ culture of bovine lactating mammary tissue.

Effect of exogenous growth hormone in early and late lactation on lactational performance of dairy cows

Bovine growth hormone (51.5 IU/day) and placebo injections were administered for 10 days to four Holstein cows in early lactation (wk 12) and again in late lactation (wk 35). Milk productions in the last 5 days of each period were compared. In early lactation, growth hormone increased milk yield by 15%, fat yield by 17%, protein yield by 14%, and lactose yield by 21%. In late lactation the respective increases were 31, 42, 18, and 35%. For responses of early and late lactation to growth hormone on a quantitative basis, increases for milk yield (4.3 versus 3.9 kg/day) and milk energy secretion (3.3 versus 3.4 Mcal/day) were similar. Concurrent with these increased milk yields, ad libitum intakes of a complete mixed diet declined during the period of growth hormone treatment by 3% in early lactation and 16% in late lactation. During the 6 h immediately following injections of growth hormone, blood plasma concentrations of growth hormone were elevated about 400% in early lactation and 700% in late lactation. Concentrations in plasma of free fatty acids were also higher during growth hormone treatment in late lactation but not in early lactation. Treatments did not affect plasma concentrations of glucose, insulin, glucagon, prolactin, tri-iodothyronine, thyroxine, or cortisol in either early or late lactation. Daily administration of growth hormone in early or late lactation resulted in similar and substantial increases of milk yield and efficiency of milk production.

Metabolic limits to milk production, especially roles of growth hormone and insulin

Potential of the bovine mammary gland to synthesize milk probably is determined fully at parturition. Realization of that potential depends on the gland receiving adequate amounts of nutrients in the correct proportions. Provided the cow is fed adequately in relation to her potential yield, supply to the body of those nutrients that are absorbed directly from the gut is not likely to limit milk synthesis. Glucose and long-chain fatty acids, however, are not absorbed from the gut in adequate amounts, and metabolic factors (primarily hormonal regulation) determining the supply of these may be important limits to milk synthesis. Even when amounts and proportions of metabolites entering circulation are adequate for maintenance and maximum milk synthesis, the cow's potential cannot be realized fully unless nutrients are channeled selectively towards the mammary gland. This occurs naturally in the high-yielding cow in early lactation and probably can be maintained artificially into midlactation by use of growth hormone. Consequences of this on milk output, health, and reproductive performance are considered.

Hormonal control of casein synthesis in organ culture of the bovine lactating mammary gland

Explants from lactating bovine mammary gland were cultured in vitro in serum-free medium though 1-9 d. casein synthesis was determined by [32P] incorporation into newly synthesized Ca rennin precipitable fraction. High correlation (r = 0.98) was found between incorporation of [32P] and [3H]amino acids in explants cultured under different hormonal regimes, thus indicating that post-translational phosphorylation is not a rate-limiting step in casein synthesis. Hormonal effects on casein synthesis were studied by supplementing the incubating medium with insulin (I), prolactin (PRL), cortisol (F), thyroxine (T4) and triiodothyronine (T3). It was found that both PRL and I were required absolutely for maximal synthesis and almost maximal effect was achieved with 50 ng/ml. The effect of F was less clear, but some increase was achieved at the 200-1000 ng/ml range. T4 and T3 did not affect casein synthesis at a range of 10(-11)-10(-7) M while a significant inhibition was observed at 2 X 10(-5) M. A time-course study of casein synthesis further substantiated the dominant role of PRL in maintenance or even elevation of the initial rate of casein synthesis in the explants, through the first 4 d of incubation.